Table 2

Sequence comparison of clinical isolates to the HAdV-A31 prototype sequence

Clinical isolate

V04-03789

0105019310

2006001610

95/8866

95/6956

96/783

95/6315

Origin

Regensburg, Germany

Hannover, Germany

Hannover, Germany

Nancy, France

Nancy, France

Nancy, France

Nancy, France

Year

2004

2001

2006

1995

1995

1996

1995

E1A

S56C, V222N (5)

E3 12.1

E34Q (1)

A5T (3)

E3 CR1 α

Q71E, N159S (9)

E3 CR1 β

Q164E, T242I (2)

T242I (7)

Q164E, T242I (3)

D130N, Q164E (2)

Q164E (3)

Q164E, T242I (4)

Q164E, T242I (2)

E3 RID β

M13V, E107G (2)

E107G (1)

E107G (1)

E107G (1)

E107G (1)

E107G (1)

E3 14.7

T106N (3)

T74A, T106N (4)

T106N (4)

T106N (5)

T106N (5)

T106N (3)

PB

F259Y (7)

F259Y(8)

FK

V40L, R62Q (4)

R62Q (4)

R62Q (3)

R62Q (3)

R62Q (3)

V40L, T53A, R62Q (5)

E4 ORF1

P119T (1)

V59L (2)

E4 ORF2

L84P (1)

E4 ORF5

R51K (6)

E4 ORF6/7

K105N, I115S (3)

The coding regions which showed amino acid substitutions in at least one isolate are listed. For each isolate, the sequence positions of amino acid substitution are noted. Additionally, the number of mutations in the nucleotide sequence is indicated in brackets.

Hofmayer et al. BMC Genomics 2009 10:557   doi:10.1186/1471-2164-10-557